首页 | 本学科首页   官方微博 | 高级检索  
检索        

甲磺酸伊马替尼预防胃肠道间质瘤术后复发效果的研究
引用本文:魏倩,王立.甲磺酸伊马替尼预防胃肠道间质瘤术后复发效果的研究[J].中国循证医学杂志,2013,13(9):1145-1148.
作者姓名:魏倩  王立
作者单位:重庆医科大学附属第一医院消化内科 重庆400016
摘    要:目的 探讨甲磺酸伊马替尼预防原发性胃肠道间质瘤(GIST)切除术后复发的效果和不良反应.方法 对2007年1月至2009年11月在成都医学院第一附属医院住院并接受手术切除,且术后经影像学检查(增强CT或增强MRI)确认无肿瘤残留的22例原发性GIST患者,于术后给予甲磺酸伊马替尼400 mg,qd口服治疗,中危患者疗程>1年,高危患者疗程>2年.观察其1年及2年无复发生存率及不良反应发生情况.结果 该22例患者中,男性13例,女性9例,中位年龄57.4岁,高危患者9例.中位随访时间34 (24 ~ 48)个月,1年无复发生存率100%,2年无复发生存率94.5%.药物不良反应主要表现为水肿、恶心、腹痛、肌肉或骨骼疼痛、血小板减少、乏力、皮疹等,多为轻度到中度,经对症处理后大多可以缓解.结论 原发性胃肠间质瘤术后使用甲磺酸伊马替尼治疗安全、有效,有可能改善患者术后无复发生存时间,预防或延迟复发.但由于未设对照,其疗效尚待进一步开展高质量的随机对照试验验证.

关 键 词:胃肠间道质瘤  甲磺酸伊马替尼  复发

Effects and Safety of Imatinib Mesylate on Preventing Postoperative Recurrence of Gastrointestinal Stromal Tumor
WEI Qian , WANG Li.Effects and Safety of Imatinib Mesylate on Preventing Postoperative Recurrence of Gastrointestinal Stromal Tumor[J].Chinese Journal of Evidence-based Medicine,2013,13(9):1145-1148.
Authors:WEI Qian  WANG Li
Institution:WEI Qian; WANG Li* Department of Gastroenterology, The First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, China
Abstract:Objective To study the effects and adverse reaction of imatinib mesylate used to prevent the recurrence of gastrointestinal stromal tumor (GIST) after resection.
Methods 22 patients with primary gastrointestinal stromal tumor were included in the First Affiliated Hospital of Chongqing Medical University from January, 2007 to November, 2009 who received resection and were imageologically diagnosed as no residual tumor by enhanced CT or enhanced MRI after resection. They were all given imatinib mesylate 400 mg for oral use daily after resection (median-risk GIST: more than 1 year; high-risk GIST: more than 2 years). Patients’ 1-year and 2-year relapse-free survival (RFS) and adverse reaction were recorded during follow-up.
Results Among 22 patients, there were 13 males and 9 females, with median age of 57.4 years, and 9 high-risk cases were included. The median follow-up lasted 34 months (24 to 48 months). Patients’ 1-year and 2-year RFS was 100% and 94.5%, respectively. Adverse reaction mainly included edema, nausea, abdominal pain, muscle or bone pain, thrombocytopenia, weakness, skin rashes, etc., most of which were mild or moderate and could be alleviated after treating symptoms.
Conclusion Imatinib mesylate therapy given after resection is a safe and reliable method which could prolong RFS and prevent or delay the recurrence of GIST. However, further high-quality randomized controlled trial was required to verify its curative effects, since no control group has been set in our study.
Keywords:Gastrointestinal stromal tumor (GIST)  Imatinib mesylate  Recurrence
本文献已被 维普 万方数据 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号